▎Cagrilintide Overview
Cagrilintide is a dual amylin and calcitonin receptor agonist (DACRA) developed based on the structure of amylin. It exerts its effects by activating the amylin receptor and the calcitonin receptor, thus demonstrating the potential to regulate metabolic parameters such as body weight and blood glucose levels.
The research and development of Cagrilintide originate from the physiological characteristics of natural amylin. Natural amylin is a hormone secreted by pancreatic cells and plays a crucial role in inducing satiety and reducing food intake. At the same time, it also participates in the regulation of blood glucose metabolism through various mechanisms, such as inhibiting the postprandial release of glucagon and delaying gastric emptying.
As a long-acting analog, Cagrilintide has a half-life of approximately 7 to 8 days. This extended half-life significantly improves the convenience of administration and patient compliance, making it a more practical treatment option.
